Running a screen on Finviz reveals that about two-thirds of the Dow’s 30 components are up by double-digit percentages in 2019. Although five of the 30 components still are basically down so…
Merrill Lynch has many stocks to buy and these are some of its top defensive stocks and dividend stocks that may help insulate investors during pullbacks or times of weakness.
Array BioPharma shares shot up on Monday after the firm announced that it would be acquired by Pfizer in an all cash transaction. The boards of directors of both companies have approved…
Chris Lange Five of the 30 Dow Jones industrials are down so far in 2019, and some more are literally just one bad day away from being down for the year.
The May 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.
The May 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.
24/7 Wall St. screened the Merrill Lynch Income Portfolio portfolio looking for high-yielding Buy-rated companies and found the following five from different sectors that are solid plays now.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers favored Apple, Intel and Pfizer above all other Dow stocks.
It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and even longer before profits can be considered.
Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the report.
Paul Ausick 24/7 Wall St. has put together a preview of Apple, Pfizer and other Dow companies scheduled to report their quarterly results this week.
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
